Brink's Receives CMA Acceptance in Principle of Proposed Remedy Relating to Pending Acquisition of NCR Atleos
The UK Competition and Markets Authority accepted in principle Brink’s proposed remedy for its planned acquisition of NCR Atleos. The remedy involves divesting NoteMachine/TestLink UK to avoid a Phase 2 referral; the acquisition remains on track to close early in the first quarter of 2027.
Why it matters — The acceptance in principle and stated closing timeline provide an update on the regulatory process and progress of Brink’s pending acquisition.